BF Biosciences Limited (PSX: BFBIO) Thursday announced that its combi filling and lyophilization lines have been commissioned and commercial production has commenced.
In a notice to the Pakistan Stock Exchange (PSX), citing an earlier communication, the company said that secured approval from Drug Regulatory of Pakistan (DRAP) for its brownfield expansion project along with commencement of commercial production from pre-filled syringes line.
“In continuation of the above, we are pleased to inform that the combi filling and lyophilization lines have been commissioned and commercial production has commenced. Accordingly, the full Line Il expansion project stands commissioned from today,” it said.
Moreover, the company said it has already secured approvals for new products from DRAP and intends to launch these products in the coming months.
Editorial & Legal Practice Group
Authored and reviewed by the corporate law and tax litigation practice group at Javid Law Associates. Our team comprises High Court advocates, corporate legal advisors, and authorized tax practitioners across Pakistan.
Advocates High Court & Tax Counsel
Jurisdiction: Pakistan